Tectonic Therapeutic, Inc. (NASDAQ: TECX) has announced favorable topline results from its Phase 1a clinical trial evaluating TX2100, an investigational antibody targeting the APJ receptor. The trial was conducted in healthy adult volunteers to support the advancement of TX2100 as a potential treatment for Hereditary Hemorrhagic Telangiectasia (HHT).
The Phase 1a trial enrolled 48 healthy adult volunteers across six sequential dose cohorts. Single ascending doses of TX2100 were administered via intravenous infusion or subcutaneous injection. The trial met its primary objectives, demonstrating that the drug was generally safe and well-tolerated. Treatment-emergent adverse events were mild or moderate and transient, with no deaths, serious adverse events, or severe adverse events reported at any dose. No clinically significant changes were observed in vital signs, laboratory assessments, or electrocardiograms.
Pharmacokinetic results indicated target-mediated drug disposition at low concentrations, confirming the drug's high affinity binding to the APJ receptor. The company plans to initiate an open-label Phase 1b clinical trial in patients with hematologic-support dependent HHT by year-end 2026. Additionally, a placebo-controlled Phase 2 clinical trial in moderate-to-severe HHT patients is scheduled to begin in early 2027. These trials are planned to run in parallel.
Regulatory milestones have also been achieved, with the U.S. FDA granting Fast Track Designation to TX2100 for HHT in September 2026. The FDA also cleared the Investigational New Drug (IND) application for the Phase 1b trial in August 2026.
